Table 14

Clinical studies of lactobacilli showing efficacy for treatment of various pathologies

BacteriaDosePathologyRef. (Design)
L. casei ShirotaNot statedVentilator-associated pneumonia291(prospective, randomised, open-label controlled study)
Synbiotic 2000
(P. pentosaceus 5—33:3, L. mesenteroides 32–77:1, L. paracasei 19 and L. plantarum 2362 + inulin, β-glucan, resistant starch and pectin)
1×1010 CFU (of each) Not statedSevere acute pancreatitis292(prospective, randomised, double-blind study)
Ecologic 641®:
(L. acidophilus, L. casei, L. salivarius, Lactococcus lactis, B. bifidum and B. lactis + cornstarch and maltodextrins)
1010 CFU (total) Not statedSevere acute pancreatitis293(multicentre randomised, double-blind, placebo-controlled study)
Genefilus F19©
(L. paracasei subsp paracasei F19
+
high-fibre diet)
12×109 CFU Not statedSymptomatic uncomplicated diverticular disease294(multicentre, randomised, controlled, open parallel-group study)
L. GG> 5×1010 CFUCirrhosis295(open study)